Aurinia Pharmaceuticals Inc. (AUPH) stock
AUPHNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 13/3058% below fair value
$15.40−0.08 (-0.52%)
Close on Nov 17, 2026Market cap $2.06BP/E 6.7Yield –
Aurinia Pharmaceuticals price to book ratio
The price-to-book ratio is market cap divided by shareholders' equity.
Aurinia Pharmaceuticals's price to book ratio was 3.5× on Nov 11, 2026, against 5.8× a year earlier. Over the last 5 years it ranged from 1.4× to 9.9×, with a median of 3.3×.
Price to Book Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 3.5× | −2.2 |
| 2025 | Dec 31, 2025 | 5.7× | +2.4 |
| 2024 | Dec 31, 2024 | 3.3× | +0.0 |
| 2023 | Dec 29, 2023 | 3.3× | +1.8 |
| 2022 | Dec 30, 2022 | 1.4× | −8.5 |
| 2021 | Dec 31, 2021 | 9.9× | +4.8 |
| 2020 | Dec 31, 2020 | 5.2× | −7.6 |
| 2019 | Dec 31, 2019 | 12.8× | +9.8 |
| 2018 | Dec 31, 2018 | 2.9× | – |
See a number that looks wrong?